论文部分内容阅读
本实验旨在研究急性髓系白血病(AML)患者中PDLIM4基因表达模型,并分析其临床相关性。运用EvaGreen实时定量PCR(RQ-PCR)方法检测AML患者中PDLIM4基因表达量。结果表明,与21例对照相比,94例AML患者PDLIM4转录本水平降低非常显著(P<0.01),共有42例(45%)AML患者为PDLIM4转录本低表达,M1/M2/M3亚型的PDLIM4低表达率非常显著地高于M4/M5/M6亚型(56%对20%,P<0.01),AML中PDLIM4低表达患者的总体生存时间(OS)显著长于非低表达者(P<0.05);受试者工作特征曲线(ROC)分析显示,ROC曲线下面积为0.865(95%可信区间:0.801-0.930),表明PDLIM4低表达对AML具有诊断意义。结论:PDLIM4低表达是一个常见事件,且对AML预后具有良性影响,可能成为潜在的诊断肿瘤的分子标记。
This experiment aimed to investigate the PDLIM4 gene expression in patients with acute myeloid leukemia (AML) and to analyze its clinical relevance. PDLIM4 gene expression in AML patients was detected by EvaGreen real-time quantitative PCR (RQ-PCR). The results showed that compared with 21 controls, PDLIM4 transcript levels were significantly decreased in 94 AML patients (P <0.01), and 42 (45%) AML patients had low expression of PDLIM4 transcripts and M1 / M2 / M3 subtypes (56% vs 20%, P <0.01). The overall survival time (OS) of patients with PDLIM4 low expression in AML was significantly longer than that in non-low expression <0.05). The receiver operating characteristic curve (ROC) analysis showed that the area under the ROC curve was 0.865 (95% confidence interval: 0.801-0.930), indicating that PDLIM4 low expression has a diagnostic significance for AML. Conclusion: The low expression of PDLIM4 is a common event and has a benign effect on the prognosis of AML. It may be a potential molecular marker for the diagnosis of tumors.